Ensysce Biosciences, Inc. (the “Firm”) (ENSC), a clinical-stage biotech firm making use of transformative chemistry to enhance prescription drug security to cut back abuse and overdose, as we speak introduced that by resolution dated February 14, 2023, a Nasdaq Hearings Panel (the “Panel”) granted the Firm’s request for continued itemizing on The Nasdaq Inventory Market (“Nasdaq”), topic to the Firm evidencing compliance with all relevant standards for continued itemizing on The Nasdaq Capital Market tier, together with the $1.00 bid worth and $2.5 million stockholders’ fairness necessities, by June 12, 2023, and the Firm’s satisfaction of sure different interim circumstances.